Biofrontera Inc.
BFRINASDAQHealthcare● Active
$0.93
$-0.01(-0.53%)
Market Cap$11907110
P/E Ratio—
52W High$1.19
52W Low$0.555
Biofrontera Inc. (BFRI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
BFRI · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 14, 2026EPS Actual
-$0.41
Est. -$0.18 · -127.8%
Revenue
$0.01B
Est. $0.01B · -1.6%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 14, 2026
After Market Close
▼ Miss EPS▼ Miss Revenue
BFRI reports quarterly as a NASDAQ-listed Drug Manufacturers - Specialty & Generic company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 12, 2026 | -$0.10 | — | — | — | $0.01B | — |
| ▼ Q2 FY2026 | May 14, 2026 | -$0.18 | -$0.41 | -127.8% | $0.01B | $0.01B | -1.6% |
| ▲ Q1 FY2026 | Mar 19, 2026 | $0.29 | $0.50 | +72.4% | $0.02B | $0.02B | +5.9% |
| ▲ Q4 FY2025 | Nov 12, 2025 | -$0.60 | -$0.59 | +1.7% | $0.01B | $0.02B | -56.7% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -$0.45 | -$0.57 | -26.7% | $0.01B | $0.01B | -5.5% |
| ▼ Q2 FY2025 | May 15, 2025 | -$0.14 | -$0.47 | -235.7% | $0.01B | $0.01B | -18.6% |
| ▼ Q1 FY2025 | Mar 21, 2025 | $0.02 | -$2.33 | -11750.0% | $0.01B | $0.01B | +19.5% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -$0.73 | -$0.86 | -17.8% | $0.01B | $0.01B | -10.0% |
Q3 FY2026
Aug 12, 2026
EPS Actual
—
EPS Est.
-$0.10
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 14, 2026Miss
EPS Actual
-$0.41
EPS Est.
-$0.18
EPS Surpr.
-127.8%
Revenue
$0.01B
Q1 FY2026
Mar 19, 2026Beat
EPS Actual
$0.50
EPS Est.
$0.29
EPS Surpr.
+72.4%
Revenue
$0.02B
Q4 FY2025
Nov 12, 2025Beat
EPS Actual
-$0.59
EPS Est.
-$0.60
EPS Surpr.
+1.7%
Revenue
$0.01B
Q3 FY2025
Aug 13, 2025Miss
EPS Actual
-$0.57
EPS Est.
-$0.45
EPS Surpr.
-26.7%
Revenue
$0.01B
Q2 FY2025
May 15, 2025Miss
EPS Actual
-$0.47
EPS Est.
-$0.14
EPS Surpr.
-235.7%
Revenue
$0.01B
Q1 FY2025
Mar 21, 2025Miss
EPS Actual
-$2.33
EPS Est.
$0.02
EPS Surpr.
-11750.0%
Revenue
$0.01B
Q4 FY2024
Nov 13, 2024Miss
EPS Actual
-$0.86
EPS Est.
-$0.73
EPS Surpr.
-17.8%
Revenue
$0.01B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.46 | $0.47 | $0.48 | 1 |
| Q3 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q2 FY2027 | $-0.07 | $-0.07 | $-0.07 | 1 |
| Q1 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q4 FY2026 | $0.41 | $0.42 | $0.43 | 1 |
| Q3 FY2026 | $-0.15 | $-0.14 | $-0.14 | 1 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▼ Q2 FY2026 | May 14, 2026 | -127.8% | $0.96 | $0.99 | +3.00% |
| ▲ Q1 FY2026 | Mar 19, 2026 | +72.4% | $0.87 | $0.86 | -1.50% |
| ▲ Q4 FY2025 | Nov 12, 2025 | +1.7% | $1.04 | $0.97 | -6.38% |
| ▼ Q3 FY2025 | Aug 13, 2025 | -26.7% | $0.93 | $0.95 | +2.15% |
| ▼ Q2 FY2025 | May 15, 2025 | -235.7% | $0.70 | $0.70 | +0.14% |
| ▼ Q1 FY2025 | Mar 21, 2025 | -11750.0% | $1.03 | $0.86 | -16.50% |
| ▼ Q4 FY2024 | Nov 13, 2024 | -17.8% | $0.94 | $0.83 | -11.54% |
| ▲ Q3 FY2024 | Aug 14, 2024 | +5.9% | $1.23 | $1.14 | -7.32% |
Q2 FY2026+3.00%
Report Date
May 14, 2026
EPS Beat/Miss
-127.8%
Price Before
$0.96
Price After
$0.99
Q1 FY2026-1.50%
Report Date
Mar 19, 2026
EPS Beat/Miss
+72.4%
Price Before
$0.87
Price After
$0.86
Q4 FY2025-6.38%
Report Date
Nov 12, 2025
EPS Beat/Miss
+1.7%
Price Before
$1.04
Price After
$0.97
Q3 FY2025+2.15%
Report Date
Aug 13, 2025
EPS Beat/Miss
-26.7%
Price Before
$0.93
Price After
$0.95
Q2 FY2025+0.14%
Report Date
May 15, 2025
EPS Beat/Miss
-235.7%
Price Before
$0.70
Price After
$0.70
Q1 FY2025-16.50%
Report Date
Mar 21, 2025
EPS Beat/Miss
-11750.0%
Price Before
$1.03
Price After
$0.86
Q4 FY2024-11.54%
Report Date
Nov 13, 2024
EPS Beat/Miss
-17.8%
Price Before
$0.94
Price After
$0.83
Q3 FY2024-7.32%
Report Date
Aug 14, 2024
EPS Beat/Miss
+5.9%
Price Before
$1.23
Price After
$1.14
Avg Beat Reaction-5.07%
Avg Miss Reaction-4.55%
Beat Rate3 / 8 quarters
Largest Move-16.50% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: BFRI ends December
Biofrontera Inc. (BFRI) most recently reported earnings on May 14, 2026 for Q2 FY2026, posting EPS of $-0.41 — missing the analyst consensus of $-0.18 by -127.8%. The next BFRI earnings date is expected around September 1, 2026.
Each quarter, investors track BFRI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. BFRI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
BFRI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
BFRI earnings · 5 questionsBiofrontera Inc.'s next earnings report is expected around September 1, 2026. BFRI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; BFRI historically reports after market close (AMC).
BFRI earnings datewhen is BFRI earningsBFRI next earnings datewhen does BFRI report earningsBFRI earnings calendar
▸ Source: FMP · Biofrontera Inc. SEC filings · US GAAP · Biofrontera Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026